Apolipoprotein M promoter polymorphisms alter promoter activity and confer the susceptibility to the development of type 1 diabetes

Abel, 2001, Pathophysiology of immune-mediated (type 1) diabetes mellitus: potential for immunotherapy, BioDrugs, 15, 291, 10.2165/00063030-200115050-00002 Sparre, 2003, Application of genomics and proteomics in Type 1 diabetes pathogenesis research, Expert. Rev. Mol. Diagn., 3, 743, 10.1586/14737159.3.6.743 Karvonen, 2000, Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group, Diabet. Care, 23, 1516, 10.2337/diacare.23.10.1516 Aribi, 2008, Candidate genes implicated in type 1 diabetes susceptibility, Curr. Diabetes Rev., 4, 110, 10.2174/157339908784220723 Pugliese, 2004, Type 1 diabetes mellitus of man: genetic susceptibility and resistance, Adv. Exp. Med. Biol., 552, 170 Xu, 1999, A novel human apolipoprotein (apoM), J. Biol. Chem., 274, 31286, 10.1074/jbc.274.44.31286 Duan, 2001, Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis, FEBS Lett., 499, 127, 10.1016/S0014-5793(01)02544-3 Wolfrum, 2005, Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis, Nat. Med., 11, 418, 10.1038/nm1211 Balakrishnan, 2002, Apolipoprotein E gene polymorphism alters lipids before pancreas transplantation, Transplantation, 74, 974, 10.1097/00007890-200210150-00013 Klein, 2004, Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses, Metabolism, 53, 1296, 10.1016/j.metabol.2004.05.004 Xu, 2006, Down-regulation of apolipoprotein M expression is mediated by phosphatidylinositol 3-kinase in HepG2 cells, Biochim. Biophys. Acta, 1761, 256, 10.1016/j.bbalip.2006.02.002 Xu, 2004, Transforming growth factor-beta down-regulates apolipoprotein M in HepG2 cells, Biochim. Biophys. Acta, 1683, 33, 10.1016/j.bbalip.2004.04.001 Huang, 2007, Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation, Med. Hypotheses, 69, 136, 10.1016/j.mehy.2006.10.052 Niu, 2007, Single nucleotide polymorphisms in the proximal promoter region of apolipoprotein M gene (apoM) confer the susceptibility to development of type 2 diabetes in Han Chinese, Diabetes. Metab. Res. Rev., 23, 21, 10.1002/dmrr.641 Shi, 2005, SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci, Cell Res., 15, 97, 10.1038/sj.cr.7290272 Xu, 2006, Suppression of apolipoprotein M expression and secretion in alloxan-diabetic mouse: partial reversal by insulin, Biochem. Biophys. Res. Commun., 342, 1174, 10.1016/j.bbrc.2006.02.022 Zhang, 2007, Hyperglycemia down-regulates apolipoprotein M expression in vivo and in vitro, Biochim. Biophys. Acta, 1771, 879, 10.1016/j.bbalip.2007.04.020 Richter, 2003, Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels, Diabetes, 52, 2989, 10.2337/diabetes.52.12.2989 Xu, 2004, Correlation of apolipoprotein M with leptin and cholesterol in normal and obese subjects, J. Nutr. Biochem., 15, 579, 10.1016/j.jnutbio.2004.03.001 Jiao, 2007, A prospective evaluation of apolipoprotein M gene T-778C polymorphism in relation to coronary artery disease in Han Chinese, Clin. Biochem., 40, 1108, 10.1016/j.clinbiochem.2007.04.023